Across TCGA pan-cancer cohorts, SMIM13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMIM13 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMIM13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMIM13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SMIM13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.848	0.305	.030	8	view →
HNSC	DFS	Tertile	All	0.852	0.622	.023	8	view →
LUAD	DFS	Quartile	All	0.830	1.000	.006	7	view →
GBM	OS	Median	All	0.224	0.530	.010	4	view →
LSCC	DFS	Median	II,III,IV	0.302	0.831	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SMIM13 tumor-vs-normal RNA expression · all SMIM13 data types